TITLE

Use of granulocyte colony-stimulating factor in patients with severe sepsis or septic shock

AUTHOR(S)
Mohammad, Rima A.
PUB. DATE
August 2010
SOURCE
American Journal of Health-System Pharmacy;8/1/2010, Vol. 67 Issue 15, p1238
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Purpose. The efficacy and safety of granulocyte colony-stimulating factor (G-CSF) in critically ill patients with severe sepsis or septic shock were evaluated. Summary. The medical literature was reviewed to identify published trials, case reports, and case series on the use of G-CSF in critically ill patients for treatment of severe sepsis or septic shock. G-CSF has been evaluated as an adjunct to standard care for critically ill patients. Initial studies involving critically ill patients with severe sepsis or septic shock found mortality benefits with G-CSF therapy; however, these findings are limited by factors such as small sample sizes, selection bias, and lack of an appropriate control group. Prospective, randomized, multicenter, double-blind studies failed to confirm the benefits in mortality for patients receiving G-CSF for the treatment of severe sepsis and septic shock. Due to the limitations in the design of the studies that report a mortality benefit and prospective, randomized, multicenter, double-blind studies that report the lack of a mortality benefit, a recommendation to add G-CSF as an adjunctive therapy in critically ill patients with severe sepsis and septic shock cannot be made at this time. Conclusion. The available data, especially those from large, prospective, randomized, double-blind studies, do not support the use of G-CSF as an adjunct therapy to standard care for critically ill patients with severe sepsis or septic shock. Data from prospective, large, randomized, controlled, well-designed studies are needed to define the optimal G-CSF dosing regimen, the safety of this therapy, and the effects of G-CSF on patient morbidity and survival.
ACCESSION #
52449249

 

Related Articles

  • Corticosteroids for severe sepsis and septic shock: a systematic review and meta-analysis. Annane, Djillali; Bellissant, Eric; Bollaert, Pierre Edouard; Briegel, Josef; Keh, Didier; Kupfer, Yizhak // BMJ: British Medical Journal (International Edition);8/28/2004, Vol. 329 Issue 7464, p480 

    Objective To assess the effects of corticosteroids on mortality in patients with severe sepsis and septic shock. Data sources Randomised and quasi-randomised trials of corticosteroids versus placebo (or supportive treatment alone) retrieved from the Cochrane infectious diseases group's trials...

  • Guiding fluid resuscitation in critically ill patients: how to evaluate the available tools? Polderman, Kees; Bein, Berthold; Kluge, Stefan; Saugel, Bernd // Intensive Care Medicine;May2015, Vol. 41 Issue 5, p962 

    A letter to the editor is presented in response to the article "Effectiveness of treatment based on PiCCO parameters in critically ill patients with septic shock and/or acute respiratory distress syndrome: a randomized controlled trial" by Z. Zhang and colleagues.

  • Severe sepsis mortality rates decreased in Australia, New Zealand.  // Infectious Disease News;Apr2014, Vol. 27 Issue 4, p29 

    The article discusses a study, led by Kirsi-Maija Kaukonen and published in a 2014 issue of the "Journal of the American Medical Association" (JAMA), on the decrease of the mortality rate of critically ill sepsis patients in New Zealand and Australia from 2000 to 2012.

  • Development of quality indicators for antimicrobial treatment in adults with sepsis. van den Bosch, Caroline M. A.; Hulscher, Marlies E. J. L.; Natsch, Stephanie; Gyssens, Inge C.; Prins, Jan M.; Geerlings, Suzanne E. // BMC Infectious Diseases;2014, Vol. 14 Issue 1, p1 

    Background Outcomes in patients with sepsis are better if initial empirical antimicrobial use is appropriate. Several studies have shown that adherence to guidelines dictating appropriate antimicrobial use positively influences clinical outcome, shortens length of hospital stay and contributes...

  • Getting down to the real question: effects of transfusion triggers on long-term survival and quality of life following septic shock. D√ľnser, Martin; Russell, James // Intensive Care Medicine;Nov2016, Vol. 42 Issue 11, p1766 

    The article examines the effectiveness of transfusion trigger in sepsis patients. The author highlights the report on the poor long-term outcome and survival of sepsis patient, the factors that affect the treatment outcome the increase of mortality rate of patients, and notes the study that...

  • "Early goal-directed therapy" versus "Early" and "goal-directed" therapy for severe sepsis and septic shock: Time to rationalize. Dhooria, Sahajal; Agarwal, Ritesh // Lung India;Sep/Oct2015, Vol. 32 Issue 5, p521 

    The authors discuss the early goal-directed therapy (EFDT), a protocolized fluid replacement therapy management on patients with severe sepsis and septic shock. The authors discusses the effectiveness of the treatment, the result of a meta-analysis which revealed that EGDT has no significant...

  • Heart rate reduction with esmolol is associated with improved arterial elastance in patients with septic shock: a prospective observational study. Biondi-Zoccai, G.; Frati, G.; Morelli, A.; Ranieri, V.; D'Egidio, A.; Orecchioni, A.; Piscioneri, F.; Greco, E.; Singer, M.; Mascia, L.; Peruzzi, M.; Guarracino, F.; Romano, S.; Ranieri, V M; Romano, S M // Intensive Care Medicine;Oct2016, Vol. 42 Issue 10, p1528 

    Purpose: Ventricular-arterial (V-A) decoupling decreases myocardial efficiency and is exacerbated by tachycardia that increases static arterial elastance (Ea). We thus investigated the effects of heart rate (HR) reduction on Ea in septic shock patients using the beta-blocker...

  • New protocol yields better outcomes.  // Healthcare Risk Management;Mar2008, Vol. 30 Issue 3, p34 

    The article reports on the result of the study conducted by the Barnes-Jewish Hospital in St. Louis, Missouri which focuses on the effectiveness of standardized hospital order set in the management of septic shock.

  • Considering CORTICUS: Hydrocortisone in Septic Shock. Akhtar, Saadia R. // Critical Care Alert;Apr2008, Vol. 16 Issue 1, p3 

    A multicenter, randomized, double-blind, placebo-controlled trial of hydrocortisone replacement in patients with septic shock found no mortality benefit in those patients with inadequate baseline response to corticotropin stimulation.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics